Our Projects
Explore our current research and development projects
C
Trial
Phase 1Navi Cell
AI-designed small molecule inhibitor targeting AP2A1 cellular senescence to disassemble aging-associated stress fibers.
NC-001C21H23N5O3S
Learn more about Navi Cell
View details
45%
K
Active
Pre-clinicalPatho Kappa
Next-gen targeted protein degrader for neurodegenerative diseases.
PK-104C28H31FN4O4
Learn more about Patho Kappa
View details
80%
C
Active
Hit-To-LeadSyntho Core
Novel immune-modulator using highly specific graph alignments.
SC-909C18H20N2O2
Learn more about Syntho Core
View details
25%